recombinant SARS-CoV-2 fusion protein vaccine / Livzon Pharma, Chinese Academy of Sciences - LARVOL DELTA

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (clinicaltrials.gov) - P3 | N=10381 | Completed | Sponsor: Livzon Pharmaceutical Group Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (clinicaltrials.gov) - P3 | N=22500 | Active, not recruiting | Sponsor: Livzon Pharmaceutical Group Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (clinicaltrials.gov) - P3 | N=10722 | Active, not recruiting | Sponsor: Livzon Pharmaceutical Group Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. (PubMed, Emerg Microbes Infect) - "Serious adverse events occurred almost equally in V-01 (0.12%) and placebo (0.16%) groups. The heterologous boosting with V-01 vaccine was safe and efficacious, which could elicit robust humoral immunity under the epidemic of the Omicron variant."

Clinical • Journal • P3 data • Fatigue • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

COVID-19: Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Tudy to Evaluate the Safety and Immunogencity (clinicaltrials.gov) - P2 | N=34 | Active, not recruiting | Sponsor: Livzon Pharmaceutical Group Inc.

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) (clinicaltrials.gov) - P1 | N=43 | Completed | Sponsor: Livzon Pharmaceutical Group Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19: Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: Livzon Pharmaceutical Group Inc.

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) (clinicaltrials.gov) - P1; N=43; Active, not recruiting; Sponsor: Livzon Pharmaceutical Group Inc.; Trial primary completion date: Aug 2021 ➔ Jan 2022

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (clinicaltrials.gov) - P3; N=10722; Recruiting; Sponsor: Livzon Pharmaceutical Group Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

COVID-19: Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization (clinicaltrials.gov) - P=N/A; N=45; Active, not recruiting; Sponsor: Livzon Pharmaceutical Group Inc.

Clinical • New trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases